KMAP Express
or
test
BEFORE MAKE A PAYMENT,
Payment is successfully settled!
We will contact you by your email
for consulting your dataset first (in 1-2 business days).
If you don't receive any email (or forgot the email address),
please contact us by our email or phone.
Developed by KaiPharm, KMAP® is a high-quality NGS-generated full transcriptomic profiling dataset for thousands of small molecule drugs approved in the United States, the European Union, and Japan at three concentrations in two cell lines with triple replicates across all conditions. The transcriptomic profiles of your drug candidates are generated under identical conditions as those of KMAP® and comparatively analyzed against ~3,000 approved drugs (KMAP® version 2021), covering a broad range of targets and indications. In contrast to other assays or experimental approaches, the dimension of comparison in KMAP Express™ is unparalleled, interrogating 20,000 genes in 50,000 samples for each requested expression profile.
KMAP Express™ is our dedicated research platform for understanding drug’s impact on cells on a genomic scale. We developed this technology specifically using our proprietary dataset, KMAP®. Our talented team empower scientists and researchers like yourself to make unexpected discoveries hidden behind the conventional knowledge. Please fill out the Inquiry Form to use our KMAP Express™ service.
Up/down-regulated (KMAP® Pathways and their corresponding genes can be inspected across samples using our web platform that is a visually informative and interactive user interface supporting instant searching, sorting, and selecting. Analytic results are conveniently presented in different formats like heatmap and plotting through our network viewer using state-of-the-art data visualization technology.
Potential (off-)targets of a drug or drug candidate are inferred on the basis of expression similarity to drugs or compounds of known targets included in KMAP®. Multiple target prediction models are applied, and a ranked list of potential off-targets is provided based on the integrated score.
The expression profiles of disease models, whether cell, organoid, or patient, are evaluated against the extensive KMAP® dataset, indicating promising drug repositioning candidates. Your drugs of interest are compared against those of KMAP®, and the top-ranked KMAP® drugs are listed on thebasis of expression similarity.
Raw data and analyzed results are downloadable securely online through KMAP Express™.
We provide high-quality RNA Seq data (cloud storage or external hard drive available) as well as sequencing QC report, notation enriched functional pathways and inferred drug (off-)targets, and compiled lists of the identified DEGs and drug repositioning candidates.
The unauthorized collection of email addresses as posted in this website by means of an automatic email address collection program or other technical devices is rejected. Please be informed that those who violate the aforementioned shall be subject to criminal punishment under the Act on Promotion of Utilization of Information and Communication Network.
① No one shall collect email addresses by means of a program automatically collecting email addresses or other technical devices from an Internet website that clearly expresses its intent of rejecting email address collection.
② No one shall sell or distribute the email addresses collected in violation of paragraph ①.
③ No one shall knowingly utilize in data transmission the email addresses prohibited from collection, sales, and distribution under the preceding paragraphs ① and ②.
